Literature DB >> 1234495

Pharmacokinetics of flucloxacillin and cloxacillin in healthy subjects and patients on chronic intermittent haemodialysis.

E H Nauta, H Mattie.   

Abstract

1 A pharmacokinetic study on flucloxacillin and cloxacillin was performed to investigate the factors contributing to the higher serum concentrations reported for the former after oral administration. 2 The results obtained in a study performed in a group of volunteers with flucloxacillin administered orally and by continuous infusion, were compared with the results of a similar investigation with cloxacillin. Patients on chronic intermittent haemodialysis received flucloxacillin orally and as a single i.v. injection. The results of this part of the study were compared with those of an earlier study on cloxacillin in haemodialysis patients. Serum and urine concentrations of flucloxacillin and cloxacillin were determined by bio-assay, and a one-compartment model was used for the calculations. 3 Higher serum concentrations reached after oral administration of flucloxacillin as compared with cloxacillin were based not only on better oral absorption (53.7% and 32.9%, respectively) but also on slower (renal and extra-renal) elimination (T1/2 : 46 and 32 min, respectively). A significant difference between the apparent volumes of distribution of flucloxacillin and cloxacillin, which could contribute to higher serum concentrations, could not be demonstrated. Considerable individual variation occurs in the rate and amount of oral absorption, especially in patients. The elimination rate of flucloxacillin in haemodialysis patients (T1/2 : 2h 53 min) corresponds with the extra-renal elimination rate in healthy subjects. No influence of haemodialysis on the elimination rate constant of flucloxacillin was found; total plasma clearance was, however, slightly but significantly higher during dialysis.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1234495      PMCID: PMC1402517          DOI: 10.1111/j.1365-2125.1975.tb01566.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  EFFECT OF UREMIA ON METHICILLIN AND OXACILLIN BLOOD LEVELS.

Authors:  R J BULGER; D D LINDHOLM; J S MURRAY; W M KIRBY
Journal:  JAMA       Date:  1964-02-01       Impact factor: 56.272

2.  CLOXACILLIN: ACTIVITY IN VITRO, AND ABSORPTION AND URINARY EXCRETION IN NORMAL YOUNG MEN.

Authors:  J W KISLAK; T C EICKHOFF; M FINLAND
Journal:  Am J Med Sci       Date:  1965-06       Impact factor: 2.378

3.  6-Aminopenicillanic acid in urine after oral administration of penicillins.

Authors:  A R ENGLISH; H T HUANT; B A SOBIN
Journal:  Proc Soc Exp Biol Med       Date:  1960-07

4.  Flucloxacillin: a new semisynthetic isoxazolyl penicillin.

Authors:  G P Bodey; C Vallejos; D Stewart
Journal:  Clin Pharmacol Ther       Date:  1972 Jul-Aug       Impact factor: 6.875

5.  [Flucloxacillin, a new staphylococcal antibiotic. In-vitro activity and pharmacokinetics].

Authors:  C Simon; V Malerczyk; B Hodgson
Journal:  Dtsch Med Wochenschr       Date:  1973-08       Impact factor: 0.628

6.  Fate of oral 35S-cloxacillin in man.

Authors:  K Hellström; A Rosén; A Swahn
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

7.  Pharmacokinetics of the new penicillins. Amoxycillin and flucloxacillin in patients with terminal renal failure undergoing haemodialysis.

Authors:  P L Oe; S Simonian; J Verhoef
Journal:  Chemotherapy       Date:  1973       Impact factor: 2.544

8.  The clearance of antibiotics by the artificial kidney.

Authors:  J Verhoef; P L Oe; S Simonian
Journal:  Chemotherapy       Date:  1973       Impact factor: 2.544

9.  Flucloxacillin, a new isoxazolyl penicillin, compared with oxacillin, cloxacillin, and dicloxacillin.

Authors:  R Sutherland; E A Croydon; G N Rolinson
Journal:  Br Med J       Date:  1970-11-21

10.  Metabolism of penicillins to penicilloic acids and 6-aminopenicillanic acid in man and its significance in assessing penicillin absorption.

Authors:  M Cole; M D Kenig; V A Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191

View more
  15 in total

1.  Drug kinetics and artificial kidneys.

Authors:  T B Gibson; H A Nelson
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

Review 2.  Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications.

Authors:  W A Craig; P G Welling
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

Review 3.  Interethnic differences in pharmacokinetics of antibacterials.

Authors:  Danny Tsai; Janattul-Ain Jamal; Joshua S Davis; Jeffrey Lipman; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2015-03       Impact factor: 6.447

4.  Pharmacokinetic analysis of cloxacillin loss in children undergoing major surgery with massive bleeding.

Authors:  M Levy; P Egersegi; A Strong; A Tessoro; M Spino; R Bannatyne; D Fear; J C Posnick; G Koren
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

5.  Mecillinam in patients on haemodialysis.

Authors:  K Bailey; J G Cruickshank; P G Bisson; B L Radford
Journal:  Br J Clin Pharmacol       Date:  1980-08       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

7.  Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig-Schippers; Jürgen B Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

8.  Active metabolites of isoxazolylpencillins in humans.

Authors:  H H Thijssen; H Mattie
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

9.  The metabolic disposition of flucloxacillin in patients with impaired kidney function.

Authors:  H H Thijssen; J Wolters
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Inhibition of flucloxacillin tubular renal secretion by piperacillin.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen B Bulitta; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Br J Clin Pharmacol       Date:  2008-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.